Why is Vertex Pharmaceuticals, Inc. ?
1
Flat results in Jun 25
- INVENTORY TURNOVER RATIO(HY) Lowest at 1.31 times
- INTEREST(Q) At USD 3.7 MM has Grown at 23.33%
- DEBTORS TURNOVER RATIO(HY) Lowest at 6.42 times
2
With ROE of -3.39%, it has a risky valuation with a 7.01 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -6.91%, its profits have fallen by -114%
3
High Institutional Holdings at 97.06%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 1.88% over the previous quarter.
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -6.91% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
How much should you hold?
- Overall Portfolio exposure to Vertex Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Vertex Pharmaceuticals, Inc. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Vertex Pharmaceuticals, Inc.
0.09%
-0.32
34.80%
S&P 500
13.22%
0.61
20.17%
Quality key factors
Factor
Value
Sales Growth (5y)
16.24%
EBIT Growth (5y)
16.29%
EBIT to Interest (avg)
51.26
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.38
Sales to Capital Employed (avg)
0.63
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
97.06%
ROCE (avg)
80.88%
ROE (avg)
19.31%
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.01
EV to EBIT
-331.34
EV to EBITDA
-844.07
EV to Capital Employed
10.64
EV to Sales
9.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.21%
ROE (Latest)
-3.39%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Movement
4What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -0.55% (YoY
NET SALES(Q)
Highest at USD 2,986 MM
OPERATING PROFIT(Q)
Highest at USD 1,227.2 MM
PRE-TAX PROFIT(Q)
Highest at USD 1,282.8 MM
-6What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.31 times
INTEREST(Q)
At USD 3.7 MM has Grown at 23.33%
DEBTORS TURNOVER RATIO(HY)
Lowest at 6.42 times
Here's what is working for Vertex Pharmaceuticals, Inc.
Net Sales
Highest at USD 2,986 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 1,227.2 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 1,282.8 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Raw Material Cost
Fallen by -0.55% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Vertex Pharmaceuticals, Inc.
Interest
At USD 3.7 MM has Grown at 23.33%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Inventory Turnover Ratio
Lowest at 1.31 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 6.42 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio






